<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432846</url>
  </required_header>
  <id_info>
    <org_study_id>IM-201</org_study_id>
    <secondary_id>2014-004510-28</secondary_id>
    <nct_id>NCT02432846</nct_id>
  </id_info>
  <brief_title>Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)</brief_title>
  <acronym>MERECA</acronym>
  <official_title>An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunicum AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunicum AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare tumor response, progression free survival (PFS) and&#xD;
      overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN:&#xD;
      ilixadencel) pre-nephrectomy followed by Sunitinib post-nephrectomy vs Sunitinib&#xD;
      post-nephrectomy patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients, all planned for nephrectomy, will be stratified according to the Heng risk criteria&#xD;
      (high risk patients vs. intermediate risk patients) and randomized in a 2:1 ratio to receive&#xD;
      Intuvax (INN: ilixadencel)+ Sunitinib or Sunitinib alone.&#xD;
&#xD;
      Two doses of Intuvax (INN: ilixadencel) will be administered in to the primary tumour before&#xD;
      nephrectomy. The control group will be scheduled for nephrectomy directly.&#xD;
&#xD;
      All patients will start Sunitinib treatment 5-8 weeks after operation.&#xD;
&#xD;
      Results from the phase I study, together with the results reported in the literature on the&#xD;
      use of autologous dendritic cells (DCs) in combination with Sunitinib encourage Immunicum AB&#xD;
      to further investigate the possibility of exploiting Intuvax (INN: ilixadencel) 10 million&#xD;
      cells/dose when combined with Sunitinib for the treatment of mRCC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS) from randomization overall in mRCC patients and by each subgroup i.e. in high-risk and in intermediate risk mRCC patients.</measure>
    <time_frame>up to 5 years after end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 months survival rate from randomization overall in mRCC patients and by each subgroup i.e. in high risk and intermediate risk mRCC patients.</measure>
    <time_frame>up to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and proportion of AEs including clinical significant changes in laboratory tests and vital signs from screening.</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) from start of Sunitinib according to RECIST 1.1.</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of objective response rate (ORR) from start of sunitinib treatment and duration of response in each subgroup.</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) from start of sunitinib treatment</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative number of tumor infiltrating CD8+ TCells in the resected primary tumor compared to related number of infiltrating CD8+ TCells in available diagnostic pre-biopsy (sample from either primary tumor or metastasis acceptable)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Renal Cell Carcinoma, Metastatic</condition>
  <arm_group>
    <arm_group_label>Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nephrectomy+Sunitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intuvax (INN: ilixadencel)</intervention_name>
    <description>Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.</description>
    <arm_group_label>Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib</arm_group_label>
    <other_name>COMBIG-DC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Cytostatic/cytotoxic drug: protein kinase inhibitor .</description>
    <arm_group_label>Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib</arm_group_label>
    <arm_group_label>Nephrectomy+Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly (&lt;6 months) diagnosed RCC (histological/cytological verification is optional)&#xD;
             with at least one (1) CT-verified metastasis ≥10mm for which complete metastasectomy&#xD;
             is not planned. US patients must have verified clear-cell tumor histology&#xD;
&#xD;
          2. Planned resection of primary tumor&#xD;
&#xD;
          3. Primary tumor diameter ≥40 mm&#xD;
&#xD;
          4. Candidate for first-line therapy with sunitinib initiated 5-8 weeks after nephrectomy&#xD;
&#xD;
          5. Female or male ≥18 years of age&#xD;
&#xD;
          6. Willing and able to provide informed consent&#xD;
&#xD;
          7. Adequate hematological parameters, i.e:&#xD;
&#xD;
               -  B-Leukocyte count ≥4.5 x10e9/L&#xD;
&#xD;
               -  B-Platelet count ≥150 x10e9/L&#xD;
&#xD;
               -  B-Hemoglobin ≥90 g/L&#xD;
&#xD;
          8. S-creatinine and S-bilirubin ≤ 1.5 x ULN. S-ALAT and S-ASAT ≤ 2.5 x ULN (or ≤5 in case&#xD;
             of liver metastases)&#xD;
&#xD;
          9. Female who has been post-menopausal for more than one (1) year or female of&#xD;
             childbearing potential agreeing to use a highly efficient method of contraception&#xD;
             (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants,&#xD;
             hormone injections, some intrauterine devices, or vasectomized partner or combined&#xD;
             birth control pills]) Female of childbearing potential must have a negative from&#xD;
             Screening until 90 days after last dose of INTUVAX and/or until completed sunitinib&#xD;
             treatment whichever occurs later.blood pregnancy test at Screening, and if randomized&#xD;
             to vaccination a negative blood or urine pregnancy test within one (1) day before each&#xD;
             dose of Intuvax) and must not be lactating.&#xD;
&#xD;
        or Male agreeing to use condoms from Screening until 90 days after last dose of INTUVAX&#xD;
        and/or until completed sunitinib treatment whichever occurs later, or male having a female&#xD;
        partner who is using a highly efficient method of contraception as described above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy less than 4 months&#xD;
&#xD;
          2. CNS metastasis that is symptomatic or progressing or untretaed or that required&#xD;
             current therapy (e.g. evidence of new or enlarging CNS metastasis or new neurological&#xD;
             symptoms attributable to CNS metastases)&#xD;
&#xD;
          3. Active autoimmune disease which requires treatment with systemic immunosuppressive&#xD;
             agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis,&#xD;
             autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus (SLE),&#xD;
             vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other&#xD;
             rheumatological diseases&#xD;
&#xD;
          4. Treatment with per oral systemic corticosteroids exceeding 10mg/day within seven (7)&#xD;
             days before Screening until nephrectomy (inhaled, intranasal and local steroids&#xD;
             accepted irrespective of dose)&#xD;
&#xD;
          5. Known cardiomyopathy and/or clinical significant abnormal ECG findings at Screening&#xD;
             disqualifying the patient from nephrectomy and from subsequent sunitinib treatment&#xD;
&#xD;
          6. Karnofsky performance status &lt;70%&#xD;
&#xD;
          7. National Cancer Institute (NCI) Common Terminology criteria for Adverse Events (CTCAE)&#xD;
             Grade 3 hemorrhage within 28 days before Screening&#xD;
&#xD;
          8. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in&#xD;
             the normal range with medication&#xD;
&#xD;
          9. Clinically significant gastrointestinal abnormalities&#xD;
&#xD;
         10. Uncontrolled hypertension, or uncontrolled diabetes mellitus&#xD;
&#xD;
         11. Pulmonary embolism within 12 months before screening&#xD;
&#xD;
         12. Prior history of invasive cancer within 5 years before screening, except for&#xD;
             adequately treated in situ carcinomas or non-melanoma skin cancer&#xD;
&#xD;
         13. Ongoing infection that requires parenteral treatment with antibiotics&#xD;
&#xD;
         14. Active or latent virus disease (HIV, hepatitis B and hepatitis C)&#xD;
&#xD;
         15. ECOG performance status &gt;2 after optimization of analgesics&#xD;
&#xD;
         16. Abnormal and clinical significant coagulation parameters at the discretion of the&#xD;
             Investigator, i.e.:&#xD;
&#xD;
               -  Prothrombin Time - International Normalized Ratio (PT-INR)&#xD;
&#xD;
               -  Activated Partial Thromboplastin Time (APTT) patients being treated with&#xD;
                  anticoagulants are excluded if the coagulation parameters are outside the&#xD;
                  therapeutic intervals as described in the SmPC/USPI for the administered&#xD;
                  treatment&#xD;
&#xD;
         17. Known major adverse reaction/event in connection with previously made vaccination&#xD;
             (e.g. asthma, anaphylaxis or other serious reaction)&#xD;
&#xD;
         18. Known hypersensitivity or allergy sunitinib or to chemically related products or&#xD;
             likely to be exacerbated to by any component of the study products&#xD;
&#xD;
         19. Prior systemic antitumour therapy within 28 days before Screening Visit. However,&#xD;
             local radiation therapy to any area except for the abdominal/retroperitoneal area&#xD;
             including the kidney tumour is allowed&#xD;
&#xD;
         20. Exposure to other investigational products within 28 days prior to Screening Visit&#xD;
&#xD;
         21. patients on anticoagulants for whom temporarily stop and start, supported by low&#xD;
             molecular weight heparin (or other anticoagulation therapy at the discretion of the&#xD;
             investigator and or per local standard of care) during vaccination and nephrectomy, is&#xD;
             not an option&#xD;
&#xD;
         22. History of alcohol or substance abuse&#xD;
&#xD;
         23. Any reason that, in the opinion of the Investigator, contraindicates that the patient&#xD;
             participates in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Börje Ljungberg, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Partners Institute</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse-Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent-Györgyi Albert Klinikai Központ</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Vesalius Sp. z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-108</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Institute of Medicine</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Onkologiczny</name>
      <address>
        <city>Wieliszew</city>
        <zip>05-135</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

